Form 8-K

8-K — Vaxart, Inc.

Accession: 0001213900-26-059127

Filed: 2026-05-19

Period: 2026-05-19

CIK: 0000072444

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0291449-8k_vaxart.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED MAY 19, 2026 (ea029144901ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0291449-8k_vaxart.htm · Sequence: 1

false

0000072444

2026-05-19

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 19, 2026

Vaxart, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-35285

59-1212264

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

310 Utah Avenue, Suite 150, South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (650) 550-3500

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

* The registrant’s common stock trades exclusively on the

OTCQX® Best Market under the symbol “VXRT.”

Item 8.01. Other Events.

May 19, 2026, Vaxart, Inc. (the “Company”) issued a letter to shareholders highlighting the Company’s clinical and operational

progress, strategic priorities and commitment to long-term value creation and urging Vaxart shareholders to support the six director nominees

nominated by the Company’s Board of Directors at the Company’s upcoming 2026 Annual Meeting of Stockholders (the “Annual

Meeting”). In the letter, the Company also addresses the nomination by a shareholder of three dissident director candidates for

election at the Annual Meeting. A copy of the Company’s letter to shareholders and press release is attached hereto as Exhibit 99.1

and is incorporated herein by reference.

The Company has scheduled

the Annual Meeting for July 16, 2026 and will file today its preliminary proxy statement and related materials with the Securities and

Exchange Commission (the “SEC”) in connection with the Annual Meeting. The Company will publish additional details regarding

the Annual Meeting in its definitive proxy statement for the Annual Meeting.

Shareholders are

encouraged to visit Vote.Vaxart.com for additional information on Vaxart’s value creation strategy,

its Board of Directors, and the Annual Meeting.

In order for a

shareholder proposal to be considered for inclusion in the Company’s proxy statement and proxy card for the Annual Meeting

pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), any such proposal

must be delivered to, or mailed to and received by, the Company’s Corporate Secretary at its corporate office at 310 Utah

Avenue, Suite 150, South San Francisco, California 94080, no later than 5:00 p.m. (Eastern Time) on May 29, 2026, prior to the time

before the Company expects to print and send its proxy materials for the Annual Meeting. Any such proposal must also meet the

requirements set forth in the rules and regulations of the SEC in order to be eligible for inclusion in the Company’s proxy

materials for the Annual Meeting. The deadline for shareholder nominations for director nominees to be considered for election at

the Annual Meeting pursuant to and in compliance with the advance notice provisions of the Company’s Amended and Restated

Bylaws has passed. To comply with the universal proxy rules, shareholders who intend to solicit proxies in support of such director

nominees other than the Company’s nominees at the Annual Meeting must provide notice to the Company setting forth the

information required by Rule 14a-19 under the Exchange Act, postmarked to the Corporate Secretary at the address provided above or

emailed to the Corporate Secretary, no later than May 29, 2026.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated May 19, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly

authorized.

Date: May 19, 2026

VAXART, INC.

/s/ Steven Lo

Steven Lo

President and Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED MAY 19, 2026

EX-99.1

Filename: ea029144901ex99-1.htm · Sequence: 2

Exhibit

99.1

Vaxart

Files Preliminary Proxy Statement and Issues Open Letter to Shareholders

Company

is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform

Emphasizes

Need for the Right Board Leadership at Critical Strategic Juncture

Encourages

Shareholders to Visit Vote.Vaxart.com for Additional Information

SOUTH

SAN FRANCISCO, Calif., May 19, 2026 -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage

biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that

it has filed preliminary proxy materials with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of

Stockholders scheduled to be held on July 16, 2026.

conjunction with the preliminary proxy filing, Vaxart issued an open letter to shareholders highlighting the Board’s urgent focus

on realizing the market potential of the Company’s unique oral vaccine platform and creating value for all shareholders. The full

text of the letter is as follows:

Dear

Fellow Vaxart Shareholders:

Vaxart

is entering a pivotal phase as we demonstrate the value of our unique oral vaccine platform and capitalize on our innovative scientific

advancements. Ahead of our upcoming 2026 Annual Meeting of Stockholders, we will be seeking your vote to support our Board of Directors,

enabling Vaxart to continue the important work underway. Over the last year, we have:

● Made

meaningful progress advancing our clinical roadmap;

● Strengthened

our near-term financial position to provide the runway to capture the potential upside from

key upcoming milestones; and

● Refreshed

and enhanced our Board with the addition of Dr. James Breitmeyer, M.D., Ph.D., who brings

more than 35 years of extensive clinical development, vaccine and regulatory experience.

While

we are making significant progress, we understand there is more work to do. We are moving with urgency, and we are focused on proving

that oral delivery is the future of vaccination. We are committed to disciplined execution to realize the market potential of our platform

and the opportunities we believe lie ahead for our shareholders.

contrast, a small group of dissident shareholders is seeking to disrupt our progress. In connection with our upcoming Annual Meeting,

they have nominated three candidates to replace highly qualified and engaged directors on our Board. Your support will be critical to

ensure we remain positioned for success and able to realize the value of your investment in Vaxart.

Driving

Clinical and Operational Progress

are strategically focusing our clinical development on areas where our Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform

can offer meaningful differentiation in areas that we believe have the potential to drive the greatest patient impact and commercial

opportunity. The Board has prudently and deliberately positioned the Company with several potential catalysts for value creation.

● COVID-19

– Platform Validation through Head-to-Head Comparison: Our Phase 2b COVID-19 trial,

conducted in collaboration with the U.S. Biomedical Advanced Research and Development Authority

(BARDA), is a cornerstone of our strategic roadmap. This trial is designed as a direct head-to-head

evaluation of our oral pill vaccine candidate against a commercially available mRNA injectable

booster. We believe this study has the potential to validate our technology and help redefine

how vaccines are delivered.

The

trial is fully enrolled with approximately 5,400 total participants across a 400-person sentinel cohort and an approximately

5,000-participant main cohort. We are working toward the release of 12-month safety data from the sentinel cohort in the second

quarter of 2026. While this sentinel data is not powered for statistical significance on efficacy, it will provide critical

directional insights ahead of the primary efficacy and safety readout from the 5,000-participant main cohort, which is currently

anticipated in early 2027.

● Norovirus

– Advancing a Potential First-in-Class Solution: Our norovirus program represents

a significant opportunity in an expanding market where no vaccine currently exists. We are

actively evaluating how our next-generation bivalent product candidate performs against the

most dominant and highly-contagious strains of norovirus, as well as other strains, while

continuing to pursue partnership and external funding opportunities to support future clinical

development activities and clinical trials.

● Influenza –

Proving Differentiation Against Market Leaders: We are continuing to develop our seasonal and avian influenza programs, which continue

to serve as important proof points for our platform’s ability to compete with market-leading injectables. We previously reported

positive data from a Phase 2 challenge study showing that our oral H1 influenza vaccine candidate was at least as protective as an approved

market-leading injectable vaccine in humans. More recently, our avian influenza vaccine was found to be 100% protective in a robust preclinical

model. These promising results demonstrate the potential of our platform for influenza, and more generally for virus protection. We are

continuing to evaluate the next steps for this program.

These

programs take time and resources, and our highly qualified Board and management team are pulling every lever to advance our programs

as quickly as possible and transition toward a sustainable commercial model.

Extending

Our Runway to Advance Our Mission

a clinical-stage biotechnology company, it is essential that we have financial resources to advance our important efforts through their

next major value-inflection points. Throughout the year, our Board and management team have taken decisive actions in an evolving regulatory

and funding environment to secure those resources, optimize our cost structure and extend our operating horizon.

Key

initiatives have significantly enhanced our financial resilience:

● Ensuring

Funding: In February 2025, BARDA issued a stop-work order for many of the vaccine programs

it was supporting. Our CEO, Steven Lo, along with Vaxart management, went to Washington D.C.

numerous times to advocate for our Company and our shareholders. Unlike many companies that

never recovered from their stop-work orders 1, Vaxart was able to restore funding

to continue our ongoing COVID-19 Phase 2b study by April 2025.

● Entering

Strategic Partnership Financing: Mr. Lo developed and finalized our strategic partnership with Dynavax

(since acquired by Sanofi) in November 2025, which has provided Vaxart with non-dilutive

cash in the near-term and the opportunity for additional payments as we hit key development

milestones. This partnership also validates the promise of our oral vaccine program.

● Operational

Efficiency: We streamlined our footprint by relocating our headquarters and reducing

fixed overhead expenses. These efforts, combined with a 21% workforce reduction implemented

in 2025, have better aligned our internal resources with our highest-priority clinical programs.

● Strategic

Capital Access: We entered into a $25 million share purchase agreement, providing a flexible

tool to bolster our balance sheet as needed to execute against our clinical milestones.

● Strong

Cash Position: We ended the first quarter of fiscal 2026 with approximately $61 million

in cash resources. Based on our current projections, this provides a funded runway into the

second quarter of 2027.

Your

Board and management team are committed to taking the necessary actions to ensure we can advance programs in a challenging environment.

While some of the actions we have already taken have been difficult – including raising dilutive financing and reducing our headcount

– we believe they have been effective in keeping Vaxart on the path to success.

Due

to the relentless efforts of our Board and management team, Vaxart has runway into the second quarter of 2027 and is

positioned to reach key upcoming clinical milestones that, if positive, are expected to provide the Company with additional

financial resources and create shareholder value.

Purpose-Built

Leadership Overseeing Value Creation

This

is an important time for Vaxart, and we believe it is critical to have the right people leading the charge, with the right experience

and relationships with key government agencies and strategic partners we need to work with. To that end, Vaxart needs a Board and leadership

team with the specific clinical, regulatory and operational experience and expertise required to navigate the intricacies of vaccine

development in a challenging regulatory and financing environment. This is not a job for director candidates who lack this

experience and expertise.

Source: The 2025 Biotech Graveyard

Our

Board and management team are purpose-built to meet these demands. Our directors are industry veterans who have “been there, done

that,” with strong track records of developing drugs, forging business relationships, and commercializing pharmaceutical solutions.

Together, they bring scientific credibility and institutional knowledge that are essential to advancing our oral vaccine programs, navigating

the complexity of the current regulatory environment and managing our financial position through critical stages of development.

The

recent addition of Dr. Breitmeyer is a prime example of our commitment to high-level expertise. Dr. Breitmeyer brings over 35 years of

directly applicable clinical and regulatory experience to our oversight efforts. We believe this specialized institutional knowledge

is vital as we move through high-stakes clinical milestones, such as our Phase 2b COVID-19 trial, which require sophisticated execution

and disciplined capital management.

Additionally,

our leadership’s interests are directly aligned with shareholders. Our directors are meaningful shareholders, including our CEO,

who personally holds more than 2.5 million shares and has never sold a single share. With holdings tied to Vaxart’s success, we

are operating with a shared sense of urgency alongside all shareholders, to ensure that every strategic decision we make is designed

to drive value.

Your

Support at Our Upcoming Annual Meeting is Important – No Matter How Many Shares You Own

Our

Annual Meeting has been scheduled for July 16, 2026.

Your participation and vote at this year’s Annual Meeting will be especially

important to ensure you can realize the value of your Vaxart investment.

While

we continue executing on our strategic priorities and positioning Vaxart for shareholder value creation, a group of shareholders has

nominated three candidates of their own to replace half of the highly qualified directors on our Board. Their nominees’ professional

biographies show no public company experience, no clinical-stage pharmaceutical experience, no financial management experience, no capital

markets experience, no regulatory experience, or any other experience that is relevant to our business.

Our

Nominating and Governance Committee and Board reviewed their nominees and determined that none of them are qualified to join our Board

in view of our established criteria for director candidates or otherwise. We believe replacing any of our highly qualified directors

with these candidates, who do not have the qualifications to steward a public company or a clinical-stage biotechnology company, would

be a value-destructive mistake.

will be providing you with more information in the weeks ahead about how you can take action in connection with our Annual Meeting to

realize the value of your investment in Vaxart.

Clear Focus on Delivering for Shareholders

Our

Board and management team are fully focused on the priorities that will drive value for shareholders. We strongly believe in the future

of our Company and the ability of our oral vaccine programs to improve health outcomes and create shareholder value. With your support,

we can capture the significant opportunities ahead.

Thank

you for your continued support of Vaxart.

Sincerely,

The

Vaxart Board of Directors

Shareholders are encouraged to visit Vote.Vaxart.com for additional information on Vaxart’s value creation strategy, its

highly qualified Board of Directors and its Annual Meeting of Stockholders.

About

Vaxart

is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.

Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk

of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines,

positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications.

Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza,

as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad

domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus

and TLR3 agonists.

Cautionary

Language Concerning Forward-Looking Statements

This

communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” provisions created by those

sections, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this

communication regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization

agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements

may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,”

“expected,” “anticipate,” “plan,” “target,” “seek,” “intend,”

“may,” “predict,” “project,” “would,” and other words and terms of similar meaning. Examples

of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product

candidates, including its vaccine booster products; Vaxart’s expectations regarding clinical results and trial data, and the timing

of receiving and reporting such clinical results and trial data; Vaxart’s expected timing for future clinical trials; and Vaxart’s

expectations with respect to the effectiveness of its product candidates; expectations regarding collaborations, including the collaboration

with Dynavax; expectations regarding the pursuit of strategic partnerships and external funding opportunities for Vaxart’s programs;

expectations regarding government funding; and expectations regarding Vaxart’s capital resources and funded runway. Vaxart may

not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements,

and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the

plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual

results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research

and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials,

regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data

and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments

by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies;

decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial

potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or

non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates

may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart

or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners’

control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and

yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel

or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain,

maintain, and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate;

Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on

terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks

and uncertainties described in the “Risk Factors” sections of Vaxart’s most recent Annual Report on Form 10-K, including

amendments thereto, and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Vaxart undertakes no obligation

to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except

as required by applicable law.

Important

Additional Information and Where to Find It

Vaxart

intends to file a preliminary proxy statement and a white proxy card with the U.S. Securities and Exchange Commission (the “SEC”)

in connection with its solicitation of proxies for the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). STOCKHOLDERS OF

THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING

WHITE PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH, OR FURNISHED TO, THE SEC IN CONNECTION WITH THE ANNUAL MEETING CAREFULLY AND IN

THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. Stockholders will

be able to obtain the Company’s proxy statement, any amendments or supplements to the proxy statement and other documents filed

by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also

be available at no charge at the Company’s website at https://investors.vaxart.com/financials-filings/sec-filings.

Participant

Information

The

Company, each of its directors (Steven Lo (President, Chief Executive Officer and Principal Executive Officer, and Director), Kevin

P. Finney, Elaine J. Heron, Ph.D., W. Mark Watson, David Wheadon, M.D., and James B. Breitmeyer, M.D., Ph.D.) and four of its

executive officers and employees in addition to Mr. Lo (Jeroen Grasman (Chief Financial Officer, Principal Financial Officer, and

Principal Accounting Officer), Sean Tucker, Ph.D. (Senior Vice President and Chief Scientific Officer), Edward B. Berg (Senior Vice

President and General Counsel), James Cummings, M.D. (Chief Medical Officer)) are deemed to be “participants” (as

defined in Schedule 14A under the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the

Company’s stockholders in connection with matters to be considered at the Annual Meeting. Information about the names of the

Company’s directors and officers, their respective interests in the Company by security holdings or otherwise, and their

respective compensation is set forth in the sections entitled “Executive Officers,” “Election of Directors,”

“Executive Compensation,” “Director Compensation,” and “Security Ownership of Certain Beneficial

Owners and Management” in the Company’s Amendment No. 1 to the Annual Report on Form 10-K, filed with the SEC on April

30, 2026 (available here). Supplemental information regarding the participants’ holdings of the Company’s securities can

be found in the Statement of Change in Ownership on Form 4 filed with the SEC on May 1, 2026 with respect to Dr. Breitmeyer,

available here through the SEC’s website and the Company’s investor relations website.

Investor

Contact

Michael

Fein

Campaign

Management

(855)

264-1527

Media

Contact

Aaron

Palash / Adam Pollack

Joele

Frank, Wilkinson Brimmer Katcher

(212)

355-4449

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 19, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 19, 2026

Entity File Number

001-35285

Entity Registrant Name

Vaxart, Inc.

Entity Central Index Key

0000072444

Entity Tax Identification Number

59-1212264

Entity Incorporation, State or Country Code

Entity Address, Address Line One

310 Utah Avenue

Entity Address, Address Line Two

Suite 150

Entity Address, City or Town

South San Francisco

Entity Address, State or Province

Entity Address, Postal Zip Code

94080

City Area Code

650

Local Phone Number

550-3500

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration